Stratos Wealth Partners LTD. Lowers Stake in Solventum Co. (NYSE:SOLV)

Stratos Wealth Partners LTD. trimmed its position in Solventum Co. (NYSE:SOLV) by 9.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,611 shares of the company’s stock after selling 929 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Solventum were worth $569,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Worldquant Millennium Advisors LLC lifted its stake in shares of Solventum by 373.6% during the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after purchasing an additional 37,600 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Solventum by 24.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock valued at $3,103,000 after buying an additional 9,333 shares during the period. The Manufacturers Life Insurance Company lifted its position in Solventum by 37.4% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after acquiring an additional 32,051 shares in the last quarter. State Street Corp boosted its holdings in Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after acquiring an additional 185,938 shares during the period. Finally, Forsta AP Fonden acquired a new stake in Solventum in the fourth quarter valued at approximately $1,876,000.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on SOLV shares. Piper Sandler boosted their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Morgan Stanley boosted their price objective on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Mizuho assumed coverage on Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Solventum currently has an average rating of “Hold” and an average price target of $68.29.

Solventum Stock Performance

Shares of Solventum stock opened at $73.57 on Wednesday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The firm’s 50-day simple moving average is $70.45 and its 200-day simple moving average is $68.20. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.